A request to dissolve filler is rarely only about removing a product. It may follow dissatisfaction with volume or shape, but it can also signal a developing medical complication. For that reason, filler dissolution timing should never be reduced to a fixed waiting period or a social-media rule. The appropriate timing depends on the filler used, the area treated, the patient’s symptoms, the interval since injection and, above all, whether blood supply or tissue health may be at risk.
In medically led aesthetic practice, the aim is not simply to make an area look different quickly. It is to assess the tissue carefully, act with appropriate urgency, and preserve the best possible long-term outcome.
Why filler dissolution timing is a clinical decision
Most elective filler dissolution involves hyaluronic acid filler, which can be broken down using hyaluronidase. This is not a universal reversal method. Hyaluronidase does not dissolve every type of dermal filler, and treatment planning must begin by establishing, as accurately as possible, what was injected, where, when and in what volume.
The timing question has two distinct meanings. The first is when to administer hyaluronidase. The second is how long to wait before judging the result, considering further treatment or reinjecting filler. These are related, but they should not be confused.
A patient who is unhappy with a recently treated lip, for example, may be experiencing expected swelling rather than excessive filler. Dissolving immediately can lead to overtreatment and an avoidable loss of naturally occurring hyaluronic acid within the tissue. Conversely, a patient with severe pain, blanching, livedo, coolness or delayed capillary refill requires urgent assessment. In that setting, waiting for swelling to settle is not a safe strategy.
The distinction is central to responsible complications management: cosmetic dissatisfaction may permit time for observation; suspected vascular compromise does not.
When urgent dissolution may be necessary
Vascular occlusion is an uncommon but serious complication of injectable treatment. It can occur when filler enters or compresses a blood vessel, compromising perfusion. Pain out of proportion, colour change, mottling, pallor, a dusky appearance, reduced warmth and altered capillary refill are all findings that demand immediate clinical attention.
Where hyaluronic acid filler is implicated, hyaluronidase may form part of an urgent, repeated treatment protocol directed by an experienced clinician. The priority is restoration of perfusion and prevention of tissue injury, not aesthetic refinement. Timing is measured in minutes and hours, not days.
Visual disturbance, severe headache, eye pain or any neurological symptom after facial filler requires emergency escalation. No patient should be advised to monitor such symptoms at home or wait for a routine appointment. Early recognition, clear documentation and decisive referral pathways are essential components of safe aesthetic medicine.
For clinicians, this reinforces the value of preparation before treatment. A complication kit without regular training, anatomical knowledge, protocols and a network for urgent referral is not an adequate safety system.
Elective dissolution after an unsatisfactory result
Not every unwanted result warrants immediate intervention. Swelling, bruising, oedema and temporary asymmetry can be pronounced during the early days after treatment, particularly in the lips and tear trough. A careful examination may show that the apparent excess is inflammatory change rather than persistent product.
In uncomplicated cases, allowing sufficient time for acute swelling to resolve often produces a clearer basis for decision-making. The exact interval varies by anatomical area and clinical presentation. Patients should be counselled before injection that the first few days do not necessarily represent the final result.
Where product migration, persistent overcorrection, a contour irregularity or an unnatural appearance is evident, elective hyaluronidase can be considered after a full consultation. The clinician should assess facial movement, skin quality, previous treatments, palpability, tissue laxity and the patient’s original anatomy. A photograph taken before treatment is often more informative than memory, especially when repeated treatments have gradually altered facial proportion.
Dissolution should be purposeful. Small, anatomically considered treatment may be preferable to indiscriminate attempts to remove all product. The aim is to improve the clinical problem while respecting the tissue plane and avoiding unnecessary depletion.
What to expect after hyaluronidase
Hyaluronidase begins to act quickly, but the visible outcome cannot always be judged immediately. Some reduction may be apparent within hours, while swelling, residual filler, fluid shift and local inflammation can obscure the true response. A review after an appropriate interval allows the clinician to decide whether further treatment is required.
Patients should understand that the area may initially appear flatter, uneven or more hollow than expected. This may reflect the previous filler masking age-related volume change, or temporary tissue response after treatment. It does not automatically mean that all native tissue support has been lost.
The enzyme’s effect is variable. It may be less predictable in older filler, in areas treated repeatedly, or where product sits in multiple planes. Ultrasound, where available and clinically appropriate, can improve diagnostic confidence by helping identify the location and behaviour of residual filler. It is particularly valuable when a history is unclear or when the clinical picture does not match the reported treatment.
A planned review also creates space for honest discussion. Some patients expect dissolution to return them precisely to their pre-filler appearance. That is not always possible, particularly after years of volumisation, changing skin quality or a significant alteration in weight and facial support.
Re-filling after dissolution: why patience matters
One of the most common questions is how soon filler can be replaced after hyaluronidase. There is no responsible universal answer. Re-treatment should follow clinical reassessment rather than an arbitrary calendar date.
The area needs time to settle so that the practitioner can evaluate volume, contour, vascular health and tissue integrity. Reinjecting too soon risks repeating the original problem, particularly if the first treatment plan was based on overcorrection, poor product placement or an unsuitable aesthetic objective.
For elective cases, a period of healing and reassessment is usually prudent before further filler is considered. The length of that period depends on the extent of dissolution, the anatomical site, whether inflammation was present and the patient’s tissue quality. In a complication, the threshold for re-treatment should be higher and the review more cautious.
A better subsequent plan may involve less filler, a different plane, a different product rheology, staged treatment or no further filler at all. In some patients, attention to skin quality, collagen stimulation, regenerative approaches or simple acceptance of natural facial anatomy may offer a more durable and proportionate path than repeated volumisation.
Assessment before treatment protects patients and practitioners
The safest consultation is forensic in its attention to detail. Practitioners should establish the product history where possible, including brand, amount, location, date, injector and any previous dissolving treatment. They should record symptoms, examine the area in good light, assess baseline asymmetry and take standardised photographs with consent.
Medical history matters. Previous allergic reactions, active skin infection, inflammatory disease, medications and a history of recurrent facial swelling may alter the risk profile or the treatment plan. Consent should address uncertainty as well as likely benefit. Hyaluronidase is a medical intervention, not a casual correction service.
Patients also benefit from being encouraged to return to their original injector where this is safe and appropriate, as that clinician may hold valuable records. However, anyone with concerning symptoms should seek prompt assessment from a suitably qualified medical professional rather than delay because records are unavailable.
Professor Patrick Treacy’s longstanding emphasis on complications education reflects a wider professional obligation: aesthetic treatments must be supported by anatomy, clinical judgement and an explicit commitment to patient safety. The most accomplished result is not the fastest correction. It is the outcome reached through sound assessment, timely action and respect for long-term tissue health.
A measured approach is the safer approach
Filler can be an effective treatment when selected and delivered well, yet every injectable procedure carries responsibilities beyond the appointment itself. Patients should retain their treatment records and seek help early if something feels wrong. Clinicians should resist pressure for instant correction when observation is appropriate, while acting without hesitation when signs indicate an urgent complication.
Good timing is not about following a single number of days. It is about recognising what the tissue is communicating, choosing the least harmful effective intervention, and allowing clinical expertise rather than anxiety to guide the next step.